---
document_datetime: 2023-09-21 21:39:50
document_pages: 25
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/sovaldi-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: sovaldi-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 15.4053937
conversion_datetime: 2025-12-23 01:31:04.235317
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Sovaldi

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| WS/2356              | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing | 12/01/2023                          | n/a                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |                       |                                                                                                                                                                                                                                                                                                                                                        |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0080              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 19/08/2022 |            | PL                    |                                                                                                                                                                                                                                                                                                                                                        |
| PSUSA/10134 /202112 | Periodic Safety Update EU Single assessment - sofosbuvir                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 07/07/2022 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                      |
| WS/2222             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Submission of the final report from study B20-146 listed as a category 3 study in the RMP. This is a non-imposed joint post-authorisation safety study to evaluate the risk of de novo hepatocellular carcinoma in patients with compensated cirrhosis treated with direct-acting antivirals for chronic hepatitis C (HCC De Novo PASS). C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission | 07/07/2022 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                        |
| SW/0079             | Post Authorisation Safety Study results - EMEA/H/C/PSR/J/0038 - Variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 24/03/2022 | 30/05/2022 | SmPC, Annex II and PL | The observational study and the systematic review/ meta- analysis did not show an increased risk of hepatocellular carcinoma recurrence in patients treated with direct-acting antivirals. The DAA-PASS study commitment is considered fulfilled and the respective products should be removed from the list of medicines under additional monitoring. |

<div style=\"page-break-after: always\"></div>

| WS/2157             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                  | 30/09/2021   | 30/05/2022   | Annex II                         |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|-----------------------------------|
| IG/1415             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                | 05/08/2021   | n/a          |                                  |                                   |
| WS/2086             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation | 08/07/2021   | 30/05/2022   | SmPC, Annex II, Labelling and PL |                                   |
| PSUSA/10134 /202012 | Periodic Safety Update EU Single assessment - sofosbuvir                                                                                                                                                                                                                                                                                     | 08/07/2021   | n/a          |                                  | PRAC Recommendation - maintenance |
| IB/0074             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                    | 25/06/2021   | 30/05/2022   | SmPC and PL                      |                                   |
| IG/1387             | B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure                                                                                                                                                                                                                                         | 18/05/2021   | n/a          |                                  |                                   |
| N/0070              | Minor change in labelling or package leaflet not                                                                                                                                                                                                                                                                                             | 17/05/2021   | 30/05/2022   | PL                               |                                   |

<div style=\"page-break-after: always\"></div>

|                     | connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                              |            |            |                                  |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------|
| IB/0072             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                               | 11/05/2021 | n/a        |                                  |                                   |
| IB/0068             | B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition)                                                                                                               | 20/11/2020 | n/a        |                                  |                                   |
| IG/1294             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                             | 01/10/2020 | n/a        |                                  |                                   |
| IG/1283             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                   | 28/08/2020 | n/a        |                                  |                                   |
| IG/1275             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 18/08/2020 | n/a        |                                  |                                   |
| PSUSA/10134 /201912 | Periodic Safety Update EU Single assessment - sofosbuvir                                                                                                                                                                                     | 09/07/2020 | n/a        |                                  | PRAC Recommendation - maintenance |
| X/0059/G            | This was an application for a group of variations. Extension application to introduce a new strength                                                                                                                                         | 30/04/2020 | 25/06/2020 | SmPC, Annex II, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | (200 mg film-coated tablets) and a new pharmaceutical form (coated granules) associated with new strengths (150 and 200 mg). The new presentations are indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients aged 3 years and above. The extension application is grouped with a type II variation (C.I.6.a) to include paediatric use in patients aged 3 to < 12 years to the existing presentations of 400 mg film-coated tablets. Sections 4.2, 4.8, 5.1 and 5.2 of the SmPC and the Package Leaflet are updated to support the extended indication. The RMP (version 10.0) is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial updates and linguistic corrections throughout the Product Information. Annex I_2.(c) Change or addition of a new strength/potency Annex I_2.(d) Change or addition of a new pharmaceutical form C.I.6.a - Change(s) to therapeutic indication(s) -   |            |     |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IG/1247 | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 08/05/2020 | n/a |

<div style=\"page-break-after: always\"></div>

|           | (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1248   | C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority                                                                                                                                                                                                                                                                                                   | 30/04/2020 | 25/06/2020 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IA/0062/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 30/04/2020 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| WS/1518   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC (Epclusa, Harvoni, Sovaldi) and 4.2, 4.4, 4.8 and 5.2 (Vosevi) in order to add new information regarding the use of the sofosbuvir-containing products in patients with renal impairment, based on final results from studies GS-US-342-4062, GS-US-                                                                                 | 19/09/2019 | 21/10/2019 | SmPC and PL | Sofosbuvir in a fixed dose combination with ledipasvir was administered for 12 weeks to 18 patients with genotype 1 chronic hepatitis C and severe renal impairment in an open-label study (Study 0154). The safety of sofosbuvir in a fixed dose combination with either ledipasvir or velpatasvir has been studied in 154 patients with ESRD requiring dialysis (Study 4062 and Study 4063). In this setting, exposure of sofosbuvir metabolite GS-331007 is 20-fold increased, exceeding levels where adverse reactions have been observed in preclinical trials. In this |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | 337-4063 and GS-US-334-0154, listed as a category 3 study in the RMP and study GS-US-338-1125. Study GS-US-342-4062 was a phase 2, multi-centre, open-label study to evaluate the efficacy and safety of sofosbuvir/velpatasvir for 12 Weeks in subjects with chronic HCV infection who are on dialysis for end stage renal disease. Study GS-US-337-4063 was a phase 2, multi-centre, open-label study to evaluate the efficacy and safety of ledipasvir/sofosbuvir in subjects with genotype 1, 4, 5 and 6 chronic HCV infection who are on dialysis for end stage renal disease. Study GS-US-334-0154 was a phase 2b, open label study of 200 mg or 400 mg Sofosbuvir+ribavirin for 24 Weeks in Genotype 1 or 3 HCV infected subjects with renal insufficiency. Study GS-US-338-1125 was a phase 1, open-label, parallel-group, single-dose study to evaluate the pharmacokinetics of voxilaprevir in subjects with normal renal function and severe renal impairment. The Package Leaflet is updated accordingly. The RMPs have also been submitted for each of the products in this work-sharing procedure. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |             | limited clinical safety data set, the rate of adverse events and deaths was not clearly elevated from what is expected in ESRD patients. The CHMP considered that safety data on the use of the sofosbuvir-based products in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m2) and end stage renal disease (ESRD) requiring haemodialysis are limited. Overall, the CHMP concluded that the sofosbuvir-based products can be used in these patients with no dose adjustment when no other relevant treatment options are available.   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10134 /201812 | Periodic Safety Update EU Single assessment - sofosbuvir                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 27/06/2019 | 23/08/2019 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s) ' for                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |             | PSUSA/10134/201812.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/1523   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.4 and 4.5 of the SmPC in order implement new information on the use of sofosbuvir- based therapy with concomitant drugs, based on final results from study GS-US-334-2130. This was a phase I study to evaluate the effects of cytochrome P450 and drug transporter inducers on sofosbuvir and probe drug pharmacokinetics in healthy subjects. Furthermore, section 4.3 of the Sovaldi SmPC was updated in order to remove the use of rifabutin as a contraindication. The Package Leaflet is updated accordingly. In addition, the Worksharing applicant (WSA) took the opportunity to introduce minor editorial changes throughout the Product Information. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 04/07/2019 | 21/10/2019 | SmPC and PL | Based on results from study GS-US-334-2130, effects of rifabutin and carbamazepine administration on the drug levels of sofosbuvir have been updated throughout the Product Information. With regards to the rifabutin interaction, a 28% reduction in sofosbuvir exposure was observed. Considering that reduction in sofosbuvir dose of <50% is expected to be safe in terms of potentially reduced efficacy, the CHMP concluded that the data support removal of co- administration of rifabutin as contraindication from the Sovaldi (sofosbuvir) Product Information. The contraindication is maintained for Epclusa, Harvoni and Vosevi, given the lack of data on interactions with the other active substances contained in these combination products. The data available for interactions with carbamazepine indicated that sofosbuvir levels were reduced by 48%, but the confidence interval included the 50% value. Therefore, the CHMP considered that a cautionary approach should be taken and contraindication concerning co-administration of carbamazepine should be retained. Furthermore, the term ' potent P-glycoprotein inducers ' was replaced by ' strong P-glycoprotein inducers ' throughout the Product Information in line with terminology used in the EMA Guideline on the investigation of drug |
| IB/0058/G | This was an application for a group of variations. B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 28/03/2019 | 23/08/2019 | SmPC        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|         | (supported by real time data) B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                           |                                                                                                                   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------------|-------------------------------------------------------------------------------------------------------------------|
| IG/1057 | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 01/03/2019 | n/a        |                           |                                                                                                                   |
| IG/1037 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 14/12/2018 | 23/08/2019 | SmPC and PL               |                                                                                                                   |
| WS/1476 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Submission of the final report from study GS-US- 334-0154, listed as a category 3 study in the RMP. This is a phase 2b randomized, open-label study of 200mg or 400mg sofosbuvir + ribavirin for 24 Weeks in genotype 1 or 3 HCV-infected subjects with renal insufficiency. The RMPs have also been submitted for each of the products in this work-sharing procedure. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 29/11/2018 | n/a        |                           |                                                                                                                   |
| R/0050  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 26/07/2018 | 17/09/2018 | SmPC, Annex II, Labelling | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            | and PL                 | Sovaldi in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10134 /201712 | Periodic Safety Update EU Single assessment - sofosbuvir                                                                                                                                                                                                                                                                                                                                                                        | 28/06/2018 | 23/08/2018 | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s) ' for PSUSA/10134/201712.           |
| T/0051              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                             | 25/04/2018 | 06/07/2018 | SmPC, Labelling and PL |                                                                                                                                                       |
| II/0048             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                   | 15/03/2018 | n/a        |                        |                                                                                                                                                       |
| WS/1328/G           | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits | 08/02/2018 | n/a        |                        |                                                                                                                                                       |
| PSUSA/10134 /201706 | Periodic Safety Update EU Single assessment - sofosbuvir                                                                                                                                                                                                                                                                                                                                                                        | 11/01/2018 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| WS/1246/G   | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation   | 30/11/2017   | n/a   |                     |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|---------------------|
| WS/1256     | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                              | 30/11/2017   | n/a   |                     |
| IG/0848/G   | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name manufacturer or an ASMF holder                                                                                                                                          | 12/10/2017   | n/a   | and/or address of a |

<div style=\"page-break-after: always\"></div>

|         | or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |                                  |                                                                            |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------|
| II/0036 | Extension of indication to add treatment of chronic hepatitis C in adolescents aged 12 to <18 years. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated in order to add information on posology, warnings, safety, efficacy and pharmacokinetics. The Package Leaflet and Risk Management Plan (RMP version 5.2) are updated in accordance. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the Product Information is brought in line with the latest QRD template version 10. C.I.6.a - Change(s) to therapeutic indication(s) - | 20/07/2017 | 14/09/2017 | SmPC, Annex II, Labelling and PL | Please refer to the Scientific Discussion Sovaldi EMEA/H/C/002798/II/0036. |
| IB/0042 | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 06/07/2017 | 14/09/2017 | SmPC                             |                                                                            |
| WS/1163 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.z - Introduction of, or change(s) to, the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 06/07/2017 | n/a        |                                  |                                                                            |

<div style=\"page-break-after: always\"></div>

|                     | obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                       |                                                                                                                                             |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10134 /201612 | Periodic Safety Update EU Single assessment - sofosbuvir                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 06/07/2017 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                           |
| WS/1075             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                          | 23/03/2017 | n/a        |                       |                                                                                                                                             |
| A20/0029            | Pursuant to Article 20 of Regulation (EC) No 726/2004, the European Commission requested the opinion of the European Medicines Agency further to a signal of hepatitis B reactivation in patients co- infected with HBV/HCV and concerns over the recurrence of hepatocellular carcinoma in patients using direct-acting antivirals in the context of interferon-free treatment of chronic hepatitis C. The PRAC was requested to assess the impact thereof on the benefit-risk balance of authorised direct-acting antivirals, namely Daklinza, Exviera, Harvoni, Olysio, Sovaldi and Viekirax and to give its opinion on whether the marketing authorisation of these products should be maintained, varied, suspended or revoked. | 15/12/2016 | 23/02/2017 | SmPC, Annex II and PL | Please refer to the assessment report: Direct-acting antivirals indicated for treatment of hepatitis C (interferon-free) - EMEA/H/A-20/1438 |

<div style=\"page-break-after: always\"></div>

| WS/1104             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                            | 16/02/2017   | n/a        |             |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-----------------------------------|
| PSUSA/10134 /201606 | Periodic Safety Update EU Single assessment - sofosbuvir                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 12/01/2017   | n/a        |             | PRAC Recommendation - maintenance |
| IG/0748             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 28/11/2016   | 23/02/2017 | SmPC and PL |                                   |
| WS/1035/G           | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation | 10/11/2016   | n/a        |             |                                   |

<div style=\"page-break-after: always\"></div>

|                     | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |             |                                                                                                                                             |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| WS/1008             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits                                                                                                                                                                                                                                                                                                                | 06/10/2016 | n/a        |             |                                                                                                                                             |
| PSUSA/10134 /201512 | Periodic Safety Update EU Single assessment - sofosbuvir                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 21/07/2016 | 19/09/2016 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s) ' for PSUSA/10134/201512. |
| WS/0980/G           | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer | 15/09/2016 | n/a        |             |                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|           | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |     |      |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|
| WS/0941   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time                                                                                                                                                                                                                                                                                                                                                                 | 23/06/2016 | n/a | data |
| WS/0904/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.z - Quality change - Active substance - Other variation B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer | 07/04/2016 | n/a |      |

<div style=\"page-break-after: always\"></div>

|         | starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the   |            |            |             |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| II/0018 | In order to address MEA 003, submission of the final study report GS-US-334-1344 to evaluate the pharmacokinetic drug-drug interaction between sofosbuvir and rifampicin. Following the review of the study result, section 4.3 of the SmPC was updated to add a contraindication for use with potent P-gp inducers. Sections 4.4 and 4.5 of the SmPC were also updated section 4.5 and the PL was updated accordingly.                                                                                                                                                                                                                                                                                                                                                                                           | 17/12/2015 | 28/01/2016 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

|                     | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |      |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------|
| PSUSA/10134 /201506 | Periodic Safety Update EU Single assessment - sofosbuvir                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 14/01/2016 | n/a        |      | PRAC Recommendation - maintenance |
| WS/0841/G           | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation | 10/12/2015 | n/a        |      |                                   |
| II/0015             | Submission of the final study report to investigate the safety and efficacy of GS-7977 and ribavirin for 24 weeks in subjects with recurrent chronic HCV post liver transplant (GS-US-334-0126). Following the CHMP discussions, section 4.2 of the SmPC is                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 22/10/2015 | 15/01/2016 | SmPC |                                   |

<div style=\"page-break-after: always\"></div>

|         | information relating to the appropriate ribavirin starting dose for the post-liver transplant population, sections 4.8 and 5.1 are updated accordingly. The submission of this study fulfils MEA 005. An updated RMP (version 3.3) is agreed. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority   |            |            |      | updated to include   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|----------------------|
| IG/0614 | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                    | 02/10/2015 | n/a        |      |                      |
|         | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                     | 14/08/2015 | 15/01/2016 | SmPC | IB/0021              |
| IG/0599 | B.I.c.2.b - Change in the specification parameters and/or limits of the immediate packaging of the AS - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                                                     | 12/08/2015 | n/a        |      |                      |
| IG/0595 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                               | 04/08/2015 | n/a        |      |                      |
| IG/0583 | A.7 - Administrative change - Deletion of                                                                                                                                                                                                                                                                                                                                                     | 23/07/2015 | n/a        |      |                      |

<div style=\"page-break-after: always\"></div>

|                     | manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |             |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| IB/0019             | C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 22/06/2015 | 15/01/2016 | SmPC and PL |                                   |
| PSUSA/10134 /201412 | Periodic Safety Update EU Single assessment - sofosbuvir                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 11/06/2015 | n/a        |             | PRAC Recommendation - maintenance |
| WS/0725/G           | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a | 21/05/2015 | n/a        |             |                                   |

<div style=\"page-break-after: always\"></div>

|           | starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                 |                                                                          |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|--------------------------------------------------------------------------|
| IG/0521   | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                                                                             | 26/02/2015 | 27/05/2015 | Annex II and PL |                                                                          |
| II/0011   | Submission of the study report AD-334-2027 (formerly P7977-2025-LPK) in order to fulfil MEA 004 - Determination of nucleotide analogue levels in liver explants from HCV infected subjects undergoing liver transplant following treatment with sofosbuvir and ribavirin. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                | 26/02/2015 | n/a        |                 | This variation lead to no changes in the product information or the RMP. |
| IA/0013   | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                          | 25/02/2015 | 27/05/2015 | SmPC            |                                                                          |
| IG/0525/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for | 02/02/2015 | n/a        |                 |                                                                          |

<div style=\"page-break-after: always\"></div>

|           | the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                          |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUV/0009 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                         | 09/01/2015 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0010/G | This was an application for a group of variations. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 18/12/2014 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0006   | Update of section 5.2 of the SmPC to reflect the results of the pre-clinical study AD-334-2024. The provision of the final study report for study AD-334- 2024 addresses MEA 012. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                | 20/11/2014 | 27/05/2015 | SmPC | The scope of this variation is to provide the final study report for pre-clinical study AD-334-2024, in order to fulfil the post-authorisation measure MEA 012. MEA is a commitment that was agreed during the CHMP assessment of the initial marketing authorisation application for Sovaldi. Study AD-334-2024 - In Vitro Inhibition Studies of Pgp, OCT1, OCT2, MATE1, OAT3, BSEP and MRP2 Transporters by High Concentrations of GS-331007 (Nucleoside Metabolite of Sofosbuvir). This study was requested by the CHMP to provide an additional analysis of the potential for pharmacokinetic |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                   |            |            |      | metabolite of SOF in plasma and excreta, with human Pgp, OCT1, OCT2, MATE1, OAT3, BSEP and MRP2 transporters. The CHMP concluded that Sofosbuvir is not a substrate for hepatic uptake transporters, organic anion transporting polypeptide (OATP) 1B1 or 1B3, and organic cation transporter (OCT) 1. While subject to active tubular secretion, GS 331007 is not a substrate for renal transporters including organic anion transporter (OAT) 1 or 3, OCT2, MRP2, P gp, BCRP or MATE1. Sofosbuvir and GS 331007 are not inhibitors of drug transporters P gp, BCRP, MRP2, BSEP, OATP1B1, OATP1B3 and OCT1. GS 331007 is not an inhibitor of OAT1, OCT2, and MATE1.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0007   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                     | 25/09/2014 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IG/0469   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                   | 07/08/2014 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0002/G | This was an application for a group of variations. Grouping of 4 variations with the submission of the final study reports for the following non clinical studies submitted in fulfilment of post-authorisation commitments for additional analysis of the potential for pharmacokinetic drug-drug interactions of sofosbuvir mediated by cytochrome P450 enzymes | 26/06/2014 | 27/05/2015 | SmPC | The final study reports for the following non clinical studies were submitted in fulfilment of post-authorisation commitments for additional analysis of the potential for pharmacokinetic drug-drug interactions of sofosbuvir mediated by cytochrome P450 enzymes (study AD-334- 2020), OAT1 transporter (study AD-334-2021), UGT1A1 enzyme (study AD-334-2022) and Pgp transporter (study AD-334-2023). The product information was updated                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|           | (study AD-334-2020 - MEA008), OAT1 transporter (study AD-334-2021 - MEA009), UGT1A1 enzyme (study AD-334-2022 - MEA010) and Pgp transporter (study AD-334-2023 - MEA011). Update of section 5.2 of the SmPC with the results from studies AD-334-2020, AD-334-2021 and AD- 334-2022. Corrections were also made to the sections 4.2, 4.5, 5.1, 5.2 of the SmPC. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission   |            |     | accordingly. The CHMP concluded that the MEAs 009, 10 and 11 were fulfilled. However, the CHMP considered that MEA008 was not fulfilled as mechanism based inhibition for CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 should also be investigated.   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0005   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 06/06/2014 | n/a |                                                                                                                                                                                                                                                              |
| IB/0003/G | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 22/05/2014 | n/a |                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|         | variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                          |            |     |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0004 | B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                         | 21/05/2014 | n/a |
| IG/0422 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location | 28/03/2014 | n/a |